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GESTATIONAL DIABETES MELLITUS (GDM): 

EXCELLENT CONTROL OR NON-DISEASE 

D. XUEREB 
INDTRODUCTION 
When it comes to gestational diabetes mellitus (GDM) 
the practising obstetrician faces a dilemma which further 
reading appears impossible to resolve. 
On the one hand there is the National Diabetes Data 
Group (I) making the case for universal screening ofthe 
obstetrical population. This has spawned a long retinue 
of followers, including several prominent members of 
the American College of Obstetrics and Gynaecology 
(ACOG). Interestingly, the latter body falls short of 
recommending universal screening, and suggests in­
stead that screening should be reserved for pregnant 
women 30 years or older unless they have risk factors (2). 
On the other hand there arc those who, like Hunter and 
Kierse (3) have examined the evidence for universal 
screening and found it lacking. They would have every­
one stop universal screening forthwith. Naylor (4) 
seriously questions the basic Oral Glucose Tolerance 
Test (OGTT) as far as methodology and assumptions 
derived therefrom. He suggests giving up the "Dichoto­
mous View" that OGTT is either normal or abnormal and 
of GDM as either present or absent. He suggests instead 
a stratification of carbohydrate intolerance into various 
degrees to which clinical significance is then applied. 
Faced with the diametrically opposite views, Landon, et 
al (5) found in a survey of ACOG members that clini­
cians practise universal screening. This is not surprising 
since Gamer and Benzie (6) have stated "until a true 
picture of the maternal fetal risklbenefit ratio is drawn, 
most centres continue to consider the gestational dia­
betic at increased risk". 
The need for a community-based popUlation study of all 
social, economic and racial groups was raised by Jacobson 
and Cousins (7) who acknowledged that all studies came 
from tertiary-care centres, not necessarily representing 
the community at large. This is why a group of obstetri­
cians in private practice calling themselves Pregna Ob­
stetrical Associates (Pregna) became interested in uni­
versal screening for GDM. 
The introduction of the glucose reflectance meter also 
contributed to our interest in the subject since it offered 
unprecedented opportunity to control glycaemia in the 
patients own home. We especially wanted to show if 
tight glucose control and close fetal surveillance could 
turn a group of patients with GDM into women with 
pregnancy risks approaching those of the general popu­
lation. 
METHOD 
The study was conducted between January 1, 1987 and 
May 31, 1990. The setting was a group private practice 
in the city of North York, Ontario (Pop. 560,000) com­
prising five obstetricians who pool their paticnts and 
work with common protocols. All patients received 
hospital management, and were del ivered. at North York 
General Hospital - a community hospital of secondary 
care designation. 
The controls were made up of two populations. Control 
population 'A' comprised all those patients who did not 
have GDM or insulin dependent diabetes mellitus and 
were delivered by the obstetrical group during the same 
time frame. Control population 'B' was made up of all 
patients, including diabetics of all classes delivered at 
North York General Hospital during the same period. 
At the ti me of their initial visit, patients were screened for 
historical high-risk markers for GDM including: previ­
ous unexplained perinatal losses, babies with congenital 
anomalies, babies weighing 4,000 g. or more 
(macrosomia); also history of g~stational diabetes in an 
earlier pregnancy or a history ofdiabetes mellitus in first­
line relatives. All patients having one or more such 
markers underwent a screening test for GDM following 
this visit. 
All other patients, and those with high-risk markers for 
GDM who screened negative initially, had a random 
50g. glucose (Glucola) test done to coincide with their 
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prenatal visit at 24-28 weeks gestation. Plasma glucose 
level was drawn and those patients with a level of 8m 
mollL or higher were considered as positive screens. 
These patients had a 3-hour 100 g. OGTT following 
three consecutive days during which their diet included 
a minimum of 150 g. of carbohydrates daily. 
All glucose laboratory tests were carried out at the same 
private lab using the glucose hexokinase method on a 
Teknicon RA I 000 analyser. 
The three hour OGTT included a fasting level drawn 
after an eight to twelve hour fast, and blood samples 
drawn at 1, 2 and 3 hours post glucose load. A positive 
OGTTwas one wherein two or more of these values were 
reached or exceeded: 
Fasting: 5.8m mollL plasma glucose 
I hour: 1O.6m mollL plasma glucose 
2 hour: 9.2m mollL plasma glucose 
3 hours: 8.1m mollL plasma glucose 
Patients with a positive OGTT were considered to have 
GDM and attended the Diabetic Clinic at North York 
General Hospital where they received instruction over a 
number of sessions from nurses and nutritionists. They 
were made aware the possible consequences of their 
glucose intolerance with respect to their pregnancy. A 
dietary history was taken and an acceptable diet of 8,500 
- 9,000 kJ given. This was to include at least 50% of the 
total caloric intake as carbohydrate, amounting to some 
40 g. per meal. 
Self monitoring of blood glucose was taught using one 
brand of reflectance meter loaned out to the patients. 
Patients were taught to calibrate the machine and to take 
4 finger prick readings daily - fasting, before lunch and 
supper, and at bedtime. They wrote down the values 
obtained in a log book which they brought to their 
prenatal visits for evaluation. Patients were encouraged 
to phone in or visit the Diabetic Clinic as often as they 
deemed necessary. 
Any patient that had two successive readings, or more 
than an occasional one of 7m mollL or higher were 
considered candidates for insulin therapy. When this 
decision was made the patients were seen in consultation 
by an endocrinologist who undertook to supervise the 
dia,betic control until delivery. N ovolin insulin usually in 
split dosage, was used and glycosylated haemoglobin 
was drawn at every prenatal visit as a double-check on 
diabetic control. 
GDM patients were seen every two weeks from diagno­
sis to the 34th week of gestation and then weekly until 
delivery. Those patients under the concurrent care of the 
endocrinologist visited him as well as the obstetrician on 
the same day and pertinent information was exchanged. 
All management related to GDM was carried out on an 
ambulatory basis. Hospitalization was for obstetrical 
and/or diabetic complications only. 
Fetal surveillance included fetal movement counting by 
the Sadovsky method (8), and an early second trimester 
ultrasound mainly for purposes of dating. Ultrasound 
examinations were repeated only on indication in later 
pregnancy: eg, polyhydramnios, twins, placenta locali­
zation, or macrosomia. From the 34th week of pregnancy 
onwards, GDM patients had weekly non-stress testing. 
Since early 1990, biophysical profiles (9) were done 
more commonly but the NST was the main test of fetal 
well-being. Patients who went beyond 40 weeks gesta­
tion were seen bi-weekly and had NST's every two to 
three days till delivery. 
Patients who showed excellent blood sugar control (3.5 
- 7m mollL) on diet alone, were allowed to go up to 42 
weeks gestation in anticipation of spontaneous labour. 
Beyond 42 weeks intervention occurred. Those patients 
requiring insulin as well as diet control were delivered at 
40 weeks. Other early deliveries were for obstetrical 
indications. 
At delivery the infants went to a transitional nursery 
where the maternal history of GDM was known. Their 
care was supervised by the family doctor or paediatri­
cian, with the help of a neonatologist where indicated. 
Beyond noting major complications, eg., anomalies, 
respiratory difficulties, and other morbidity, eg ., infec­
tion or hyperbilirubinaemia, affecting length of hospital 
stay, the nursery course of the infants was not part of the 
protocol for this study. 
At the six weeks post-partum office visit, all GDM 
patients were encouraged to have a repeat 3-hour OGTT 
with a 75g. glucose load. Those patients with a positive 
test were contacted and advised to make lifestyle changes 
including diet and weight-loss where indicated. Regular 
glucose testing under the supervision of the family 
doctor was encouraged. 
RESULTS 
Between January 1, 1987 and May 31, 1990, Pregna 
Obstetrical Associates (Pregna) delivered 3,774 patients. 
Of these, 147 patients tested positive for GDM, for an 
incidence of 3.9%. Seven-hundred and twenty-seven 
(727) patients, 19% had a positive glucose challenge test 
and 20% of these (147) had an abnormal OGTT. 
Of the 147 GDM patients, two moved elsewhere before 
completing their pregnancy. Thus only 145 patients' 
histories were fully analysed, although data from 147 
were used for epidemiological purposes. 
Table I summarizes the patient totals. 
The obstetrical population at Pregna draws from all 
groups of the rich multicultural mix of the region. One 
group, Orientals, is made up mostly of Chinese from 
Hong Kong with small percentages ofTaiwanese, main­
land Chinese, and Vietnamese. According to the 1986 
census (Statistcs Canada) North York has between 5% 
---
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TABLE I 
GESTATIONAL DIABETES MELLITt:S (GDM) 
Study per;od: 1 January 1987 - 31 ~ay 1990 -I 
--I 
Total Deliveries n = 3774 

GDM Patients n = 147* 0.9%) 

Control Populations; 
"A": 	 Total deliveries less diabetics 
(All classes) 
n =3622 
"B"; 	 Total deliveries @ NYGH 

during study period 

n = 9435 

*2 patients delivered elsewhere 
and 8% Orientals. At Pregna, patients of oriental extrac­
tion numbered 672 in the study, ie., 20.5% of the total 
obstetrical load. Of these 672 patients, 56 or 38[lc were 
diagnosed as having GDM. 
TABLE 11 
PATIENT AGE 
j 
GDM patient age and parity are shown in table Il and Ill. 
In table II, one sees a relatively smaller percentage of 
women under 25 years of age in the study group com­
pared to control s and a higher percentage of women aged 
40 years or older. The num bers are too small to allow for 
statistical analysis. 
The parity of the study and control populations were 
similar. (Table TIl). A breakdown of the parous women 
by number of viable pregnancies again failed to show 
significant differences. 
The risk factors for gestational diabetes identified at the 
first prenatal visit are presented in Table IV. Where 
patients had more than one risk factor only one was 
counted. The rates for these historical events were not 
noted in the control populations. 
As noted, only 35% of the GDM population had histori­
cal risk factors for GDM. The corollary is that 657c of 
GDM patients had none. Thus 94 of 3,774, or 2.5% of 
patients had GDM without any historical markers. 
Of 141 GDM patients, 131 were managed by diet alone, 
whereas 14 or 9.6% required the addition of insulin to 
STUDY CONTROL 
AGE POPULATION POPULATION "A" 
(YRS) n = 145 n = 3622 
. ---- -----, 
:s; 24 4 
25 - 29 54 
I 30 - 34 55 
35 - 39 27 
::0:40 5 
--	---rr-
I TOTALS 	 145 
TABLE III 
PATIENT PARITY 
1­
(2.8 c70 ) 
(37.2%) 
(38.0o/r) 
(l~.6'10) 
(3.4%) 
(100%) 
STUDY 
POPULATION 
PARITY 
c-­
n = 147 
Nulliparous 
~ Par_o_us__ I 
61 (41%) 
86 (59%) 
----­
355 (9.8%) 
1148 (31.7%) 
1456 (40.2%) 
605 (16.7%) 
58 (1.6%)
1-- ----­

_1­
--j 
I 
3622 (100%) 
CONTROL 
POPULATION "A" 
n = 3622 
1666--:6~) --l 
1956 (54%) 
TOTALS 	 I 147 (100%) 3622 (100%) I 
__I~ 
----- -- -- --
I 
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TABLE IV 
CLASSICAL RISK FACTORS IN PAST MEDICAL I 
08S. HISTORY (n =147) 
--- ---- --Ir 
• Previous S.B.. N.N.D.. Rec. AB\! 
• Previous Babies B.W. ;:0: 4 Kg 
• Previous Babies with Congo Anom. 
• G.D.M. in earlier Preg. 
• Family history ofD.M. 
Total 
I 
L 
achieve glucose stabilizati on. There were no instances of 
hyperglycaemic coma and hypoglycaemic attacks were 
transient, of mild nature, and managed effectively by the 
patients themselves. 
Only two patients required briefhos­ TABLE VII 
pitalization for stabilization. These CESAREAN SECTION RATE (%) 
were thought due to compl iance prob­
i 	 ' 
lems compounded by language/cul­	 GDM I CONTROLS I CONTROLS ·1 
tural differences. 
"A" 	 "B" 
I 
n = 145 	 n = 3622 n = 9435A total of 23 patients out of 145 
GDM patients (15.8%) had labour 1- ­
induced: This is comparable to 10Gj, , PRTlv1ARY 
in control population "A" and 17% in I ELECTIVE 10.8 
"'8", 
REPEAT/
'/
Of the 23 patients having induced 
labour, six were for "elective" rea­ ____FA~J~DV~~l ~2 
sons and were mostly in the early I TOTALS I part of the study. The other 17 had 
indications as shown in table V. 
TABLE V 
REASONS FOR INDUCTION (n =23) 
Elective 
Indicated 
• Post Date~ 	 6 
• Abnormal NST 	 2 
• A AB.S./ B.P. 	 5 
• Prom 38 wks x > 34 hrs 
• Bad Obs. Hx 
• Prev. Prccip. Lab. 
TABLE VI 
MODE OF DELIVERY (n =139) 
Spontaneous / Low forceps 76 
Mid-Forceps 25 
Primary C/S 20 
Repeat C/S 18 
Term Breech o 
4 
9 
2 
6 
31 I 
-----i 
52 
I (35%) J 
The mode of delivery of 139 GDM patietns is shown in 
table VI. In six patients it was unclear whether forceps 
delivery was low or mid. These patients were excluded 
from the analysis. 
The mid forceps rate of 18% is similar to that in both 
control groups. It should be noted that a strict definition 
of mid forceps (Caput not distending the introitus) is 
used at the hospital. Also the incidence of epidural 
analgesia/anaesthesia use is 51 % overall in both the 
study population and controls. 
Table VII shows the caesarean section rates in the study 
and control population. Twelve of eighteen elective 
repeat caesarean sections were done at patients' request. 
The obstetrician's input contributing to the patient choices 
is an unmeasured quantity. There is no statistically 
-~ 
significant difrerence in caesarean section rates between 
groups. 
Table VIII lists the indications leading to the 20 primary 
6 
caesarean 	 sections done. Cephalopelvic disproportion 
17 	 leads the list with five (250/,,) as it does in all such lists. 
Significantly, five ofthe caesarean sections (25%) were 
done for complicated twin gestations. Another 3 (15%) 
were for complicated breech presentations while Prema­
ture Rupture or Membranes (PROM) contributed an­
other 3 (159c). The other indications were PROM with 
high head (2). fetal distress in labour (2), PROM and 
cord prolapse (I). failed inductions (I), and traumatic 
previous vaginal delivery. ~ 
The distribution of birth weights is shown in Fig. 1. When 
compared with the two control populations, these figures 
are practically identical. In fact, when macrosomia is 
considered the study group had a rate of I J .2% while (54.6% ) 
control population "B" 11.3%. (18.0%) 
( 14.3%) Table IX lists the factors associated with the 23 deliver­
(13.0%) 	 ies prior to 37 weeks of gestational age. The total 
prematurity rate was 15.9%. If one subtracts three twin 
gestations and three conditions incompatible with life, 
l- -I 
14.3 J 1.2 9.5 
5.9 
13.0 	 7.8 6.8 
I N/A 
___ ~.9 
---1 
27.3% IY% 16.3(;(I 
---'--------- ----~ 
--- - - -- ---------
-----
---
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one obtains a corrected prematurity rate of 11.7%. This 
compares with 4% in control population "B". 
Of the maternal complications, Pregnancy Induced Hy­
pertension (PIH) was by far the most common - seen in 
seven or 4.8% of the GDM patients. This compares to a 
rate of 4O/C in control populations "B". 
TABLE VIII 
PRIMARY CESAREAN SECTION INDICATIONS 
(n =20) 
ic;D, F~ILURE TO PROGR~SS. ETC.-­ 5 
PIH + PREMATURE TWINS 4 
BREECH + OTHER COMPUC. E.G. PIH 3 
PROM + HIGH STATION 2 
FETAL DISTRESS IN LABOllR 2 
PROM + CORD PROLAPSE 
PREVOUS BIG BABY (# CLA V.) 
TWINS - "A" BREECH 
FAILED INDUCTION 
TABLE IX 

The identified fetal complications are shown in table X. 
There were two perinatal deaths out of ISO infants for a 
perinatal mortality rate of 13/ 1,000. Both babies had 
anomalies incompatible with life - one had Down's 
Syndrome with hypoplastic left heart, and the other non­
immune hydrops from homologous alphathalassaemia 
associated with multiple anomalies. Both babies died 
within hours of delivery. 
One fetus weighed 41 Og. at 21 weeks of gestation and 
was stillborn. The mother had cervical incompetence. 
This patient had GDM in a previous pregnancy and 
tested positive again in the index prcgnancy. Her GDM 
was well controlled by diet alone and autopsy of the fetus 
revealed no major anomalies. 
Missing from the list of causes of fetal morbidity are 
hypoglycaemia, hyperbilirubinaemia and polycythaemia. 
No precise figures are known but judging from length of 
stay in the nursery, these complications were not a 
significant contribution to overall morbidity. 
DISCUSSION: 
There are widely varying prevalence rates for GDM 
quoted from different parts of the world (10). Rates also 
vary within the same country depending on the popula-
PREMATURE DELlVERY<37 Weeks (n = 23) 
I G.A. (WKS) ASSOCIATED FACTORS 	 n 
h5 
36 TWIN 

PIH 3 s 

NONE 4 

PROM - BREECH 2 
HOMOL. a - THAL I 4 
NONE 
34 	 ABRUPTION 

PIH 3 

NONE 

33 	 TWIN 

PROM - BREECH 4 

PIH 

I 
~ FM - AB NOR. NSTL ___ 
32 TWIN 2 

PROM - CHORIO 

27 PROM 2 

DOWN SYN. (CHD) 

21 CERVICAL INCOM 

PREMATURITY RATE 	 231145 15.9';0 
CORRECTED PREM. RATE 171145 11.7°k 
I (TWINS & COND. INCOMP. WITH L~FE) 
I CONTROLS "B" 
___ 4.0% _I 
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FIGURE 1 BIRTH WEIGHT (G) G.D.M. 
(n= 150)* 
50 = I 
40 ­
t ~-
20­
n
-
10 ­
0 ­
g>~ j/ / tI~ /' /! g>~ / / 
cv , . cv / "' ,
' !' ' ! /
/ I] ! / B... / I] I ! ~ L 3L I L~ / 
*SPAIRS OF TWINS 
TABLE X: FETAL COMPLICATIONS (n = 8) 
PERINATAL DEATHS 

DOWN SYN. with CHD 

HOMOL a - THAL. with HYDROPS 

IMMATURITY (21 WKS - 4 109 B,W,) 
MORBIDITY 

LOW APGAR «4 @ 1', <7 @ 5') 

CHORIOAMNIONITIS - LU. INFECTION 

TRANSIENT TACHYPNOEA 

ABRUPTIO PLAC. 

PROLAPSE CORD 

tion tested, Thus Jacobson and Cousins (7) found an 
incidence of 4.3% GDM among over 2,000 patients in 
Loma Linda, California. Hispanics were more likely to 
have GDM than other ethnic groups in this study. The 
high incidence ofGDM in the Pima Indian has been well 
documented (11). 
In this study the overall rate of GDM was 3.9% which is 
close to Jacobson and Cousins' rate in the population­
based study quoted above. It is also within the range of 
1-5% quoted by Hadden (10). Our findings of a higher 
rate of GDM in the oriental population within our study 
group may have implications for the region. Since immi­
gration from the Far East to North America has increased 
significantly in recent years, and since there appears to 
be an increased incidence of carboydrate intolerance in 
female offspring of GDM women (12), this higher inci­
dence of GDM in orientals may have a long term impact. 
In spite of ACOG recommendations to limit screening of 
pregnant women without risk factors for GDM to those 
over 30 years ofage (2), there is no doubt that carboydrate 
intolerance can be picked up much earlier. In Coustan et 
tI / /$ ~ 
'" " '\f 0
' / §// I ~/!B ~ / ~I 9 
!!] 
Ol 
­
2 (13/1000) 
1 
5 
aI's study (13) 56% of the GDM patients were under 30 
years old. They were using the low threshold value of 
130mg/dL (7,2m mollL) on their 50g. glucose screen. In 
the present study, using the higher threshold value of 8m 
mollL, 40% of the GDM patients were below 30 years of 
age. This would suggest screening should not be limited 
by age. 
The limiting of screening to patients with historical risk 
factors forGDM alone as suggested by Sullivan (14) has 
been frequently challenged. Our data suggests that screen­
ing only those with historical risk factors would result in 
a large number of undetected GDM patients. 
Garner and Benzie (6) reviewed the data which supports 
universal screening rather than by risk factors alone. 
Our choice of the 8m mollL threshold (1 44mg./dL) for 
the 50g. glucose screen was somewhat arbitrary. So is the 
commonly used threshold of 7.2m mollL (135 mg./dL) 
(\5). The value we chose came closest to O'Sullivan's 
original threshold of 143 mg/dL which corresponds to 
7.9m moUL (14). Various thresholds have been used by 
Maltese Medica l Journal 52 Volume V Issue 2 1993 
different investigators, which contributes significantly 
to the muddying ofthe waters in an area that can use more 
clarity and uniformity. Coustan et al (13), aiming for 
100% sensitivity opted for 7.2m mollL (130 mg./dL). 
Sacks et al (15) used a 7 .5m mollL (135 mg./dL) cut-off 
while Beard et al (16) used 7.8m mollL (l40mg./dL). 
Others such as Marquette and Skoll (17) suggest a 8.3m 
mollL (150 mg./dL) threshold which would identify 
88% of patients who would be picked up by a 7.2m moll 
L (130 mg./dL) threshold but at 40% of the cost. Given 
the fact that a patient may test above or below the given 
threshold on two successive days (15) one may choose to 
opt for a lower rather than a higher threshold. On the 
other hand by putting the threshold at 8m mollL we still 
get some 88% sensitivity with a specificity of over 80% 
(6) with considerable cost saving and fewer unnecessary 
tests. Even with our relati vely high threshold, a full 19% 
(727 patients) of our study population had a positive 50g. 
screen and of these, I in 5 had an abnormal OGTT. 
Bringing the threshold down lower increases the number 
of patients having to undergo OGTT and probably picks 
up patients with extremely mild carbohydrate intoler­
ance. 
An area of even bigger confusion is that relating to the 
use of insulin in GDM. There have been suggestions that 
all GDM patients should be given insulin (18, 19) claim­
ing reduced incidence of macrosomia and subsequent 
difficult delivery. These studies had methodological 
flaws. The only randomized trial comparing diet versus 
diet and insulin therapy showed no difference in mater­
nal glucose control or neonatal outcome (20). 
Accepting that insulin should be used only in cases 
where diet alone has failed to keep the GDM in good 
control is the first step. Established criteria on which to 
base intervention with insulin do not exist. Langer would 
start insulin when fasting "plasma" values are above 
5.3m mollL: Coustan, when the fasting "plasma" is over 
5.3m mollL or the 2-hour P.e. "plasma" level is 6.6/L or 
over: Gabbe uses a fasting "plasma" level of 5.8m moll 
L or a 2-hour P.e. "capillary" level of 7.7m mollL (21). 
In our study we chose to initiate insulin therapy when two 
consecutive reflectance meter (capillary) readings are 
7m mollL or higher or when readings in this range are 
more thanjust isolated. Using these criteria, we had 9.6% 
of our GDM patietns who required insulin. Jacobson and 
Cousins (7) had an incidence of 11 .5% of GDM patients 
requiring insulin. Their criteria were different from ours 
requiring a fasting (capillary) glucose level of over 5.5m 
mollL or a 2-hour p.c. level of greater than 7.2m mollL. 
The use of the reflectance meter for home self-monitor­
ing of blood glucose levels has made a great difference 
in the management of diabetes mellitus in general. Landon 
et al (22) point out that the capillary blood following a 
finger stick is primarily arterial and has a higher glucose 
concentration that venous blood. Hanson et al (23) 
compared hospital care between 32 and 36 weeks and 
out-patient self-monitoring in a prospective, randomized 
study and found no significant difference in perinatal 
morbidity . Our experience with reflectance meters is that 
patients of different background and intelligence had no 
trouble using them. The patients felt they were signifi­
cantly involved in their own management and this in­
creased their motivation to do well. 
Macrosomia in this study was defined as a baby wieghing 
4,000 g. or more at birth. The designation LGA or large 
for gestational age (greater than the 90 percentile for 
gestational age) is a more accurate measure of intra­
uterine overgrowth. However, the term macrosomia has 
worked its way into the literature of GDM to the point 
where using it makes more sense for purposes of com­
parison. Boyd et al (24) found that the incidence of 
macrosmia in infants weighing over 2,500 g. at birth in 
the general obstetrical population has remained un­
changed since the early 1960's. It is against such a 
backdrop that discussions about macrosomia in GDM 
have to be tested. Another pertinent point to make is that 
the majority of macrosomic infants are born to mothers 
with a normal OGTT (3). 
That untreated maternal hyperglycaemia of prolonged 
duration will resit in macrosomia in more patients than in 
controls is not questioned. The problem arises when one 
tries to correlate macrosomia with GDM. Some (25,26) 
have reported rates of macrosomia as high as 30% when 
mothers have GDM. In fact, Langer et al (27) and 
Lindsay et al (28) have reported a higher incidence of 
macrosomia in patients with just one abnormal value on 
OGTT and who, therefore, fall short of being technically 
gestational diabetics. 
However, Boyd et al (24) concluded that wide applica­
tion of an OGTT to pregnant women would be of limited 
value in identifying those with increased risk of fetal 
macrosomia. Also Pettitt et al (11) found glucose con­
centration, maternal weight and maternal age to be 
strongly related to each other and to macrosomia. After 
the confounding factors were removed by binary multi­
ple regression analysis, third trimester glucose concen­
tration was no longer significantly associated with 
macrosomia. 
Furthermore, Thomson et al (29) warn that since the 
incidence of macrosomia is 10% in the normal pregnant 
population, one should be concerned about programs 
that could potentially reduce this level below "normal" 
as well as the effects of manipulating fetal growth in all 
women with GDM, the majority of whom have babies of 
normal weight. Langer et al (30) found that babies born 
to mothers with persistently low mean blood sugars, had 
a 20% incidence of} UGR. They found that mothers with 
glycaemic control ranging between 4.8 - 6m mollL tend 
to have babies in the range comparable to the overall 
obstetrical popUlation. 
At the present study, macrosomia was found in 11.2% of 
the GDM pateints and 11.3% of the general obstetrical 
population ("B). We chose to interpret this as having 
achieved the desired effect of glycaemic control in our 
study popUlation. The other interpretation, ie., that there 
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are as many as GDM patients in control group "B" as in 
the study population is less likely since the rate of 
macrosomia in both groups is very close to the 1 0% rate 
for "normal" obstetrical population sited by Boyd et al 
(24) and Thomson et al (29). 
The induction rate of 15.8% in the study population is 
high compared to the 10% in control group "A" but 
similar to control group "B" which was 17%. Because of 
the style of group practice, the obstetricians within 
Pregna have elective induction of labour is quite uncom­
mon. Within a subset of patients such as those that 
constitute a study group, there will be some who are 
rather anxious about their medical condition. Also the 
concept of allowing patients with GDM to go beyond the 
40 weeks of gestation is relatively recent (21, 30) and 
early in the study, the obstetricians were anxious as well. 
When the GDM patients have excellent glycaemic con­
trol, and the fetus grows normally and has normal bio­
physical tests , we now feel confident that they are at 
normal risk for perinatal mortality. Coustan (21) and De 
Muylder (31) agree. 
The maternal complication of note in the study was PIH: 
4.8%. This rate is similar to that in the control group of 
Gerneretal(32). In that study, PIH was twice as common 
in GDM patients as in control - 9.9% vs. 4.3%. Lindsay 
et al (28) had results similar to Garner et aI's with a 
doubling of PIH rates GDM. In fact they even found an 
increased risk of PIH in patients with only one OGTT 
abnormal value. Tallarigo et al (33) observed and in­
creased risk of pre-eclampsia eclampsia in women with 
"limited degrees of hyperglycaemia". They conceded 
that this association was possibly the result of confound­
ing and bias which their study could not identify or 
quantify. Since De Muylder (31) found PIH more fre­
quently when GDM was diagnosed after the 32nd week 
of gestation, it is possible that the normal rate of PIH in 
this study population denotes early diagnosis and good 
glycaemic control. 
As expressed earlier, this study had a very small compo­
nent dealing with neonatal morbidity. No comments can 
be made pertaining to such possible complications as 
hypoglcaemia, hyperbilirubinaemia, and polycythaemia 
in the nursery. Hunter and Kierse (3) reviewed the 
literature and concluded that the case for increased risk 
of hypoglycaemia and neonataljaundice is weak.]n fact 
they clai m that the risk ofperinatal mortality and morbid­
ity has been "considerably over-emphasized". On the 
topic of perinatal mortality, Coustan (21) says that as 
long as patients are identified and carefully managed, the 
risk should not be increased. De Muylder (31) uses the 
same logic and concludes that the rate and severity of the 
neonatal complications should be minimal. 
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